

Audit Review Table						
University Health Care (UHC) dba Passport Health Plan (PHP) (Org ID: 1559, SubID: 4152, Medicaid, Spec Area: None, Spec Proj: None); Measurement Year - 2012						
The Auditor lock has been applied to this submission.						
Pharmacy Reversal - Pharmacy Reversals Included						
Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
Effectiveness of Care: Prevention and Screening						
Adult BMI Assessment (aba)	Y		N	76.38%	R	Reportable
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (wcc)	Y		N			
<i>BMI Percentile</i>				60.49%	R	Reportable
<i>Counseling for Nutrition</i>				64.02%	R	Reportable
<i>Counseling for Physical Activity</i>				44.37%	R	Reportable
Childhood Immunization Status (cis)	Y		N			
<i>DTaP</i>				88.50%	R	Reportable
<i>IPV</i>				97.79%	R	Reportable
<i>MMR</i>				95.35%	R	Reportable
<i>HIB</i>				97.79%	R	Reportable
<i>Hepatitis B</i>				97.57%	R	Reportable
<i>VZV</i>				95.58%	R	Reportable
<i>Pneumococcal Conjugate</i>				87.83%	R	Reportable
<i>Hepatitis A</i>				80.53%	R	Reportable
<i>Rotavirus</i>				74.12%	R	Reportable
<i>Influenza</i>				51.55%	R	Reportable
<i>Combination #2</i>				87.17%	R	Reportable
<i>Combination #3</i>				82.74%	R	Reportable
<i>Combination #4</i>				73.67%	R	Reportable
<i>Combination #5</i>				65.93%	R	Reportable
<i>Combination #6</i>				47.79%	R	Reportable
<i>Combination #7</i>				60.40%	R	Reportable
<i>Combination #8</i>				45.13%	R	Reportable
<i>Combination #9</i>				40.71%	R	Reportable
<i>Combination #10</i>				38.94%	R	Reportable
Immunizations for Adolescents (ima)	Y					
<i>Meningococcal</i>				75.00%	R	Reportable
<i>Tdap/Td</i>				86.95%	R	Reportable
<i>Combination #1</i>				73.45%	R	Reportable
Human Papillomavirus Vaccine for Female Adolescents (hpv)	Y			29.40%	R	Reportable
Lead Screening in Children (lsc)	Y		N	82.30%	R	Reportable
Breast Cancer Screening (bcs)	Y			51.67%	R	Reportable
Cervical Cancer Screening (ccs)	Y			64.11%	R	Reportable
Chlamydia Screening in Women (chl)	Y					
<i>16-20 Years</i>				63.14%	R	Reportable
<i>21-24 Years</i>				69.62%	R	Reportable
<i>Total</i>				65.00%	R	Reportable
Effectiveness of Care: Respiratory Conditions						
Appropriate Testing for Children with Pharyngitis (cwp)	Y	Y		73.57%	R	Reportable
Appropriate Treatment for Children With URI (uri)	Y	Y		77.74%	R	Reportable
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis (aab)	Y	Y		31.99%	R	Reportable
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (spr)	Y			33.57%	R	Reportable
Pharmacotherapy Management of COPD Exacerbation (pce)	Y	Y				
<i>Systemic Corticosteroid</i>				38.20%	R	Reportable
<i>Bronchodilator</i>				56.01%	R	Reportable
Use of Appropriate Medications for People With Asthma (asm)	Y	Y				
<i>5-11 Years</i>				92.95%	R	Reportable
<i>12-18 Years</i>				87.98%	R	Reportable
<i>19-50 Years</i>				67.74%	R	Reportable
<i>51-64 Years</i>				58.02%	R	Reportable
<i>Total</i>				87.88%	R	Reportable
Medication Management for People With Asthma (mma)	Y	Y				
<i>5-11 Years - Medication Compliance 50%</i>				70.54%	R	Reportable
<i>5-11 Years - Medication Compliance 75%</i>				48.49%	R	Reportable
<i>12-18 Years - Medication Compliance 50%</i>				63.53%	R	Reportable
<i>12-18 Years - Medication Compliance 75%</i>				42.29%	R	Reportable
<i>19-50 Years - Medication Compliance 50%</i>				71.20%	R	Reportable
<i>19-50 Years - Medication Compliance 75%</i>				56.00%	R	Reportable
<i>51-64 Years - Medication Compliance 50%</i>				91.30%	R	Reportable
<i>51-64 Years - Medication Compliance 75%</i>				71.74%	R	Reportable
<i>Total - Medication Compliance 50%</i>				68.37%	R	Reportable
<i>Total - Medication Compliance 75%</i>				47.17%	R	Reportable
Asthma Medication Ratio (amr)	Y	Y				
<i>5-11 Years</i>				75.14%	R	Reportable
<i>12-18 Years</i>				66.79%	R	Reportable
<i>19-50 Years</i>				43.32%	R	Reportable
<i>51-64 Years</i>				40.74%	R	Reportable
<i>Total</i>				68.23%	R	Reportable
Effectiveness of Care: Cardiovascular						

Cholesterol Management for Patients With Cardiovascular Conditions (cmc)	Y		N			
<i>LDL-C Screening Performed</i>				79.91%	R	Reportable
<i>LDL-C Control (<100 mg/dL)</i>				44.59%	R	Reportable
Controlling High Blood Pressure (cbp)	Y			62.97%	R	Reportable
Persistence of Beta-Blocker Treatment After a Heart Attack (pbh)	Y	Y		73.42%	R	Reportable
Effectiveness of Care: Diabetes						
Comprehensive Diabetes Care (cdc)	Y		N			
<i>Hemoglobin A1c (HbA1c) Testing</i>				84.08%	R	Reportable
<i>HbA1c Poor Control (>9.0%)</i>				35.57%	R	Reportable
<i>HbA1c Control (<8.0%)</i>				55.97%	R	Reportable
<i>HbA1c Control (<7.0%)</i>				41.85%	R	Reportable
<i>Eye Exam (Retinal) Performed</i>				52.74%	R	Reportable
<i>LDL-C Screening Performed</i>				76.99%	R	Reportable
<i>LDL-C Control (<100 mg/dL)</i>				42.54%	R	Reportable
<i>Medical Attention for Nephropathy</i>				79.48%	R	Reportable
<i>Blood Pressure Control (<140/80 mm Hg)</i>				42.04%	R	Reportable
<i>Blood Pressure Control (<140/90 mm Hg)</i>				64.68%	R	Reportable
Effectiveness of Care: Musculoskeletal						
Disease Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis (art)	Y	Y		44.21%	R	Reportable
Use of Imaging Studies for Low Back Pain (lbp)	Y			68.09%	R	Reportable
Effectiveness of Care: Behavioral Health						
Antidepressant Medication Management (amm)	Y	Y				
<i>Effective Acute Phase Treatment</i>				60.50%	R	Reportable
<i>Effective Continuation Phase Treatment</i>				46.60%	R	Reportable
Follow-Up Care for Children Prescribed ADHD Medication (add)	Y	Y				
<i>Initiation Phase</i>				29.12%	R	Reportable
<i>Continuation and Maintenance (C&M) Phase</i>				28.83%	R	Reportable
Follow-Up After Hospitalization for Mental Illness (fuh)	Y	N				
<i>30-Day Follow-Up</i>				NB	R	Required benefit not offered
<i>7-Day Follow-Up</i>				NB	R	Required benefit not offered
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medication (ssd)	Y	Y		75.96%	R	Reportable
Diabetes Monitoring for People With Diabetes and Schizophrenia (smd)	Y			60.87%	R	Reportable
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (smc)	Y			80.00%	R	Reportable
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (saa)	Y	Y		57.63%	R	Reportable
Effectiveness of Care: Medication Management						
Annual Monitoring for Patients on Persistent Medications (mpm)	Y	Y				
<i>ACE Inhibitors or ARBs</i>				91.01%	R	Reportable
<i>Digoxin</i>				91.45%	R	Reportable
<i>Diuretics</i>				91.02%	R	Reportable
<i>Anticonvulsants</i>				59.94%	R	Reportable
<i>Total</i>				87.59%	R	Reportable
Access/Availability of Care						
Adults' Access to Preventive/Ambulatory Health Services (aap)	Y					
<i>20-44 Years</i>				85.12%	R	Reportable
<i>45-64 Years</i>				90.68%	R	Reportable
<i>65+ Years</i>				92.07%	R	Reportable
<i>Total</i>				88.22%	R	Reportable
Children and Adolescents' Access to Primary Care Practitioners (cap)	Y					
<i>12-24 Months</i>				97.85%	R	Reportable
<i>25 Months - 6 Years</i>				89.37%	R	Reportable
<i>7-11 Years</i>				91.95%	R	Reportable
<i>12-19 Years</i>				91.64%	R	Reportable
Annual Dental Visit (adv)	Y	Y				
<i>2-3 Years</i>				42.27%	R	Reportable
<i>4-6 Years</i>				67.93%	R	Reportable
<i>7-10 Years</i>				67.87%	R	Reportable
<i>11-14 Years</i>				63.59%	R	Reportable
<i>15-18 Years</i>				57.11%	R	Reportable
<i>19-21 Years</i>				39.64%	R	Reportable
<i>Total</i>				60.95%	R	Reportable
Initiation and Engagement of AOD Dependence Treatment (iet)	Y	N				
<i>Initiation of AOD Treatment: 13-17 Years</i>				NB	R	Required benefit not offered
<i>Engagement of AOD Treatment: 13-17 Years</i>				NB	R	Required benefit not offered
<i>Initiation of AOD Treatment: 18+ Years</i>				NB	R	Required benefit not offered
<i>Engagement of AOD Treatment: 18+ Years</i>				NB	R	Required benefit not offered
<i>Initiation of AOD Treatment: Total</i>				NB	R	Required benefit not offered
<i>Engagement of AOD Treatment: Total</i>				NB	R	Required benefit not offered
Prenatal and Postpartum Care (ppc)	Y					
<i>Timeliness of Prenatal Care</i>				85.91%	R	Reportable
<i>Postpartum Care</i>				69.35%	R	Reportable

Call Answer Timeliness (cat)	Y			69.89%	R	Reportable
Utilization						
Frequency of Ongoing Prenatal Care (fpc)	Y					
<21 Percent				2.46%	R	Reportable
21-40 Percent				1.79%	R	Reportable
41-60 Percent				4.70%	R	Reportable
61-80 Percent				12.98%	R	Reportable
81+ Percent				78.08%	R	Reportable
Well-Child Visits in the First 15 Months of Life (w15)	Y		N			
0 Visits				1.25%	R	Reportable
1 Visit				1.46%	R	Reportable
2 Visits				2.62%	R	Reportable
3 Visits				4.06%	R	Reportable
4 Visits				7.96%	R	Reportable
5 Visits				14.66%	R	Reportable
6+ Visits				67.98%	R	Reportable
Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (w34)	Y		N	70.68%	R	Reportable
Adolescent Well-Care Visits (awc)	Y		N	52.46%	R	Reportable
Frequency of Selected Procedures (fsp)	Y				R	Reportable
Ambulatory Care: Total (amba)	Y				R	Reportable
Ambulatory Care: Dual Eligibles (ambb)	Y				R	Reportable
Ambulatory Care: Disabled (ambc)	Y				R	Reportable
Ambulatory Care: Other (ambd)	Y				R	Reportable
Inpatient Utilization--General Hospital/Acute Care: Total (ipua)	Y				R	Reportable
Inpatient Utilization--General Hospital/Acute Care: Dual Eligibles (ipub)	Y				R	Reportable
Inpatient Utilization--General Hospital/Acute Care: Disabled (ipuc)	Y				R	Reportable
Inpatient Utilization--General Hospital/Acute Care: Other (ipud)	Y				R	Reportable
Identification of Alcohol and Other Drug Services: Total (iada)	Y	N			R	Required benefit not offered
Identification of Alcohol and Other Drug Services: Dual Eligibles (iadb)	Y	N			R	Required benefit not offered
Identification of Alcohol and Other Drug Services: Disabled (iadc)	Y	N			R	Required benefit not offered
Identification of Alcohol and Other Drug Services: Other (iadd)	Y	N			R	Required benefit not offered
Mental Health Utilization: Total (mpta)	Y	N			R	Required benefit not offered
Mental Health Utilization: Dual Eligibles (mptb)	Y	N			R	Required benefit not offered
Mental Health Utilization: Disabled (mptc)	Y	N			R	Required benefit not offered
Mental Health Utilization: Other (mptd)	Y	N			R	Required benefit not offered
Antibiotic Utilization: Total (abxa)	Y	Y			R	Reportable
Antibiotic Utilization: Dual Eligibles (abxb)	Y	Y			R	Reportable
Antibiotic Utilization: Disabled (abxc)	Y	Y			R	Reportable
Antibiotic Utilization: Other (abxd)	Y	Y			R	Reportable
Relative Resource Use						
Relative Resource Use for People With Diabetes (rdi)	Y				R	Reportable
Relative Resource Use for People With Asthma (ras)	Y	Y			R	Reportable
Relative Resource Use for People With Cardiovascular Conditions (rca)	Y				R	Reportable
Relative Resource Use for People With Hypertension (rhy)	Y				R	Reportable
Relative Resource Use for People With COPD (rco)	Y				R	Reportable
Health Plan Descriptive						
Board Certification (bcr)	Y				R	Reportable
Total Membership (tjm)	Y				R	Reportable
Enrollment by Product Line: Total (enpa)	Y				R	Reportable
Enrollment by Product Line: Dual Eligibles (enpb)	Y				R	Reportable
Enrollment by Product Line: Disabled (enpc)	Y				R	Reportable
Enrollment by Product Line: Other (enpd)	Y				R	Reportable
Enrollment by State (ebs)	Y				R	Reportable
Race/Ethnicity Diversity of Membership (rdm)	Y				R	Reportable
Language Diversity of Membership (ldm)	Y				R	Reportable
Weeks of Pregnancy at Time of Enrollment in MCO (wop)	Y				R	Reportable